Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Dairo Rodelo-Barrios has a total of 74 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Strategies for Early Liberation from Mechanical Ventilation in the Intensive Care Unit After Coronary Artery Bypass Grafting: A Scoping Review

    by Elber Osorio-Rodríguez, Andrés Ortega-Ovalle, José Contreras-Chajin, Daniel Botero-Alonso, Dairo Rodelo-Barrios, Diego González-Betancur, Juan Serrato-Buitrago, Aldair Guette-Lobato, Yassid Nuñez-Beyeh, José Correa-Guerrero, et al.

    Early liberation from mechanical ventilation is an important component of postoperative care after coronary artery bypass grafting (CABG), but the strategies, extubation-readiness criteria, and reported outcomes remain heterogeneous. This scoping review mapped early ventilator liberation strategies, clinical extubation criteria, and relevant outcomes in adults undergoing CABG. Following Joanna Briggs Institute methodology and PRISMA-ScR, PubMed/MEDLINE, Web of Science, Cochrane CENTRAL, ScienceDirect, and SciELO were searched from inception to 31 December 2025. Evidence was synthesized descriptively. Of 2374 records identified, 19 studies published between 1977 and 2025 were included. Eleven evaluated automated weaning, five clinical early-extubation protocols, one a non-automated ventilatory strategy, and two observational assessments. Central values for time to extubation ranged from 1.8 to 18.2 h. Eight studies reported a statistically significant reduction in time to extubation, seven found no significant difference, and the comparison was not evaluable in four. Readiness criteria included hemodynamic, gas-exchange, neurological, spontaneous-breathing, and bleeding-control domains, whereas safety outcomes were inconsistently reported. The evidence was heterogeneous and did not establish the superiority of any strategy. Standardized readiness criteria, uniform time definitions, and consistent reporting of clinical and safety outcomes are needed to improve comparability and applicability.

  • Open Access

    Role of Lipoprotein(a) in Aortic Valve Calcification: Inflammatory and Oxidative Mechanisms Involved

    by Alberto Polo-Barranco, Carlos Rebolledo-Maldonado, Dairo Rodelo-Barrios, Juan Solano-Ropero, Valentina Rada-Obeso, Carlos Lavalle-Jiménez, Valeria Blanchar-Martínez, Carlos Beltran-Sánchez, Augusto Maza-Arnedo, Thalia Herrera-Calvo, et al.

    Elevated plasma lipoprotein(a) [Lp(a)] levels represent a predominantly genetically determined risk factor for atherosclerotic cardiovascular disease and calcific aortic valve disease (CAVD). Mechanistically, Lp(a) transports oxidized phospholipids, lysophosphatidylcholine, and autotaxin, components capable of promoting inflammation, oxidative stress, and valvular fibrocalcific remodeling. This review synthesizes the molecular, cellular, and clinical evidence linking Lp(a) to CAVD progression. Retention of Lp(a) and other apolipoprotein B-containing lipoproteins in the valvular matrix promotes endothelial activation, recruitment of cells of the monocytic lineage, and the release of proinflammatory mediators. Oxidized phospholipids and the autotaxin–lysophosphatidic acid axis activate redox-dependent pathways and promote the transition of valvular interstitial cells toward myofibroblastic and/or osteogenic phenotypes. These processes converge in alterations in cholesterol metabolism, the release of procalcifying extracellular vesicles, and hydroxyapatite nucleation. Genetic and imaging evidence supports an association between elevated Lp(a), microcalcifying activity, and accelerated hemodynamic progression. Although anti-Lp(a) therapies substantially reduce plasma Lp(a) concentrations, their effect on valvular outcomes has not yet been demonstrated.

  • Open Access

    Severe Metabolic Acidosis in Intensive Care: Implications for Acute Kidney Injury, Bicarbonate, and Renal Replacement Therapy

    by Carlos Rebolledo-Maldonado, Juan Solano-Ropero, Elber Osorio-Rodríguez, Aleyda Parra-Castillo, Carlos Beltran-Sánchez, Neil Martínez-Fontalvo, Diego González-Betancur, Dairo Rodelo-Barrios, Manuel Cueto-Chaparro, José Correa-Guerrero, et al.

    Severe metabolic acidosis is a frequent finding in the intensive care unit (ICU) and a critical marker of clinical severity and organ dysfunction, closely linked to acute kidney injury (AKI) due to shared physiological mechanisms and the loss of the kidney’s ability to maintain acid-base homeostasis. Therefore, it represents the biochemical expression of heterogeneous pathophysiological mechanisms related to acid-base balance. These include tissue hypoperfusion, sepsis, mitochondrial dysfunction, accumulation of unmeasured anions, bicarbonate loss, and reduced renal excretion of the acid load. Its presence is associated with increased mortality, greater vasopressor and mechanical ventilation requirements, prolonged ICU stay, and a higher likelihood of renal replacement therapy (RRT). However, pH correction alone does not guarantee clinical improvement. Therefore, contemporary management prioritizes the etiology, severity of the acidemia, and hemodynamic status. In this context, sodium bicarbonate plays a limited and selective role, particularly in severe acidemia with advanced AKI or hyperkalemia, or as temporary supportive therapy while the underlying cause is corrected or extracorporeal support is arranged. Similarly, RRT should be reserved for refractory cases and should not be initiated based solely on isolated pH thresholds. This review analyzes the definition, epidemiology, clinical implications, pathophysiology, and therapeutic strategies for severe metabolic acidosis in critically ill patients, with emphasis on its interaction with AKI, the rational use of bicarbonate, and the timing of RRT initiation.

  • Open Access

    Role of Lipoprotein(a) in Aortic Valve Calcification: Inflammatory and Oxidative Mechanisms Involved

    by Alberto Polo-Barranco, Carlos Rebolledo-Maldonado, Dairo Rodelo-Barrios, Juan Solano-Ropero, Valentina Rada-Obeso, Carlos Lavalle-Jiménez, Valeria Blanchar-Martínez, Carlos Beltran-Sánchez, Augusto Maza-Arnedo, Thalia Herrera-Calvo, et al.

    Lipoprotein(a) [Lp(a)] is a predominantly genetic risk factor for atherosclerotic cardiovascular disease and calcified aortic valve disease (CAVD). In addition to its epidemiological and genetic association with aortic stenosis, Lp(a) transports oxidized phospholipids, lysophosphatidylcholine, and autotaxin, components capable of promoting inflammation, oxidative stress, and valvular fibrocalcifying remodeling. This review synthesizes the molecular, cellular, and clinical evidence linking Lp(a) to CAVD progression. Retention of Lp(a) and other apolipoprotein B-containing lipoproteins in the valvular matrix promotes endothelial activation, monocyte and macrophage recruitment, and the release of proinflammatory mediators. Oxidized phospholipids and the autotaxin-lysophosphatidic acid axis activate redox-dependent pathways and promote the transition of valvular interstitial cells to myofibroblastic and osteogenic phenotypes. These processes converge in alterations in cholesterol metabolism, the release of procalcifying extracellular vesicles, and hydroxyapatite nucleation. Genetic and imaging evidence support an association between elevated Lp(a), microcalcifying activity, and accelerated hemodynamic progression. Although anti-Lp(a) therapies substantially reduce plasma Lp(a) concentrations, their effect on valvular outcomes has not yet been demonstrated.

  • Open Access

    Severe Metabolic Acidosis in Intensive Care: Implications for Acute Kidney Injury, Bicarbonate, and Renal Replacement Therapy

    by Carlos Rebolledo-Maldonado, Juan Solano-Ropero, Elber Osorio-Rodríguez, Aleyda Parra-Castillo, Carlos Beltran-Sánchez, Neil Martínez-Fontalvo, Diego González-Betancur, Dairo Rodelo-Barrios, Manuel Cueto-Chaparro, José Correa-Guerrero, et al.

    Severe metabolic acidosis is a frequent finding in the intensive care unit (ICU) and a critical marker of clinical severity and organ dysfunction, closely linked to acute kidney injury (AKI) due to shared physiological mechanisms and the loss of the kidney's ability to maintain acid-base homeostasis. Therefore, it represents the biochemical expression of heterogeneous pathophysiological mechanisms related to acid-base balance. These include tissue hypoperfusion, sepsis, mitochondrial dysfunction, accumulation of unmeasured anions, bicarbonate loss, and reduced renal excretion of the acid load. Its presence is associated with increased mortality, greater vasopressor and mechanical ventilation requirements, prolonged ICU stay, and a higher likelihood of renal replacement therapy (RRT). However, pH correction alone does not guarantee clinical improvement. Therefore, contemporary management prioritizes the etiology, severity of the acidemia, and hemodynamic status. In this context, sodium bicarbonate plays a limited and selective role, particularly in severe acidemia with advanced AKI or hyperkalemia, or as temporary supportive therapy while the underlying cause is corrected or extracorporeal support is arranged. Similarly, RRT should be reserved for refractory cases and should not be initiated based solely on isolated pH thresholds. This review analyzes the definition, epidemiology, clinical implications, pathophysiology, and therapeutic strategies for severe metabolic acidosis in critically ill patients, with emphasis on its interaction with AKI, the rational use of bicarbonate, and the timing of RRT initiation.

  • Open Access

    Acute Kidney Injury in Severe Dengue: Current Evidence and Knowledge Gaps in Latin America

    by Carlos Rebolledo-Maldonado, Alberto Polo-Barranco, Mary Ramos-Rincón, Carlos Martínez-Castillo, Ana Barraza-Peña, Luz Ceballos-Madrid, Dairo Rodelo-Barrios, Helman Diaz-Ramírez, Valeria Blanchar-Martínez, Carlos Beltran-Sánchez, et al.

    Dengue remains a major public health problem in tropical and subtropical regions, particularly in Latin America. Acute kidney injury (AKI) is one of the severe complications associated with dengue and has been linked to worse clinical outcomes, including prolonged hospitalization, need for renal replacement therapy, and increased mortality. This review aimed to summarize the available evidence on the epidemiology, pathophysiology, clinical manifestations, diagnosis, management, and prognosis of dengue-associated AKI, while also providing an overview of the literature from Latin America. This manuscript was developed as a narrative review. For the Latin America-specific overview, a focused structured search was conducted in PubMed, ScienceDirect, Cochrane Library, LILACS, and Web of Science, including studies published up to December 2025. The available data suggest that AKI in dengue is multifactorial, involving plasma leakage, renal hypoperfusion, endothelial dysfunction, tubular injury, rhabdomyolysis, thrombotic microangiopathy, and inflammatory renal damage. Clinically, AKI has been associated with oliguria, proteinuria, elevated serum creatinine, renal replacement therapy, and higher mortality. Only four eligible indexed studies from Latin America were identified in our search, all from Brazil, with small sample sizes and incomplete reporting of renal outcomes; however, additional unpublished or non-indexed local data may exist. In summary, dengue-associated AKI is a relevant complication of severe dengue, but the evidence available from Latin America remains limited. These findings highlight the need for improved renal surveillance and standardized reporting in dengue-endemic settings across Latin America.


  • Open Access

    PaCO2 as a Possible Treatable Trait in Acute Respiratory Failure: A Scoping Review

    by Carmelo Dueñas-Castell, José Correa-Guerrero, Dairo Rodelo-Barrios, Luis Valderrama-Ortiz, Cristhian Vallejo-Burgos, Diana Borré-Naranjo, Amilkar Almanza-Hurtado, Elber Osorio-Rodríguez

    Acute respiratory failure (ARF) often leads to ICU admission, ventilatory support, illness, and death. The usual classification into hypoxemic and hypercapnic types does not capture its full complexity. Precision medicine uses the concept of “treatable traits” to guide care based on traits that are clinically relevant, identifiable, measurable, and possibly changeable. Arterial carbon dioxide pressure (PaCO2) reflects factors like alveolar ventilation, dead space, respiratory mechanics, and how patients respond to ventilatory support. This makes it clinically relevant in selected situations. We carried out a scoping review using PRISMA-ScR and JBI guidelines to summarize evidence on hypocapnia and hypercapnia as prognostic, stratification, or clinically relevant variables during respiratory support. We searched PubMed/MEDLINE, ScienceDirect, and Web of Science (1994–2025), and checked references by hand. Thirty-four studies met our criteria and were grouped into four areas: pre-intubation or early acute presentation, non-invasive support (NIV/HFNC), invasive mechanical ventilation (IMV), and weaning or post-extubation. In summary, hypocapnia was linked to worse outcomes or failure of support in hypoxemic or cardiogenic cases. Hypercapnia helped identify patients who benefited from NIV, such as those with chronic obstructive pulmonary disease or obesity hypoventilation. For IMV, the effects depended on the presence and severity of acidosis and on its duration. Overall, PaCO2 showed context-dependent clinical relevance, acting mainly as a prognostic or stratification marker and, in narrower settings, as a variable that may inform monitoring or support decisions. This review provides a pragmatic framework for interpreting PaCO2 across respiratory support contexts and highlights the need for safe and clinically meaningful targets.


  • Open Access

    Acute Kidney Injury in Severe Dengue: Current Evidence and a Latin American Overview

    by Carlos Rebolledo-Maldonado, Alberto Polo-Barranco, Mary Ramos-Rincón, Carlos Martínez-Castillo, Ana Barraza Peña, Luz Ceballos-Madrid, Dairo Rodelo-Barrios, Helman Diaz-Ramírez, Valeria Blanchar-Martínez, Carlos Beltran-Sánchez, et al.

    Dengue remains a major public health problem in tropical and subtropical regions, particularly in Latin America. Acute kidney injury (AKI) is one of the severe complications associated with dengue and has been linked to worse clinical outcomes, including prolonged hospitalization, need for renal replacement therapy, and increased mortality. This review aimed to summarize the available evidence on the epidemiology, pathophysiology, clinical manifestations, diagnosis, management, and prognosis of dengue-associated AKI, while also providing an overview of the literature from Latin America. This manuscript was developed as a narrative review. For the Latin America-specific overview, a focused structured search was conducted in PubMed, ScienceDirect, Cochrane Library, LILACS, and Web of Science, including studies published up to December 2025. The available data suggest that AKI in dengue is multifactorial, involving plasma leakage, renal hypoperfusion, endothelial dysfunction, tubular injury, rhabdomyolysis, thrombotic microangiopathy, and inflammatory renal damage. Clinically, AKI has been associated with oliguria, proteinuria, elevated serum creatinine, renal replacement therapy, and higher mortality. Only four eligible indexed studies from Latin America were identified in our search, all from Brazil, with small sample sizes and incomplete reporting of renal outcomes; however, additional unpublished or non-indexed local data may exist. In summary, dengue-associated AKI is a relevant complication of severe dengue, but the evidence available from Latin America remains limited. These findings highlight the need for improved renal surveillance and standardized reporting in dengue-endemic settings across Latin America.


  • Open Access

    PaCO₂ as a Possible Treatable Trait in Acute Respiratory Failure: A Scoping Review

    by Carmelo Dueñas-Castell, José Correa-Guerrero, Dairo Rodelo-Barrios, Luis Valderrama-Ortiz, Cristhian Vallejo-Burgos, Diana Borré-Naranjo, Amilkar Almanza-Hurtado, Elber Osorio-Rodríguez

    Acute respiratory failure (ARF) often leads to ICU admission, ventilatory support, illness, and death. The usual classification into hypoxemic and hypercapnic types does not capture its full complexity. Precision medicine uses the idea of “treatable traits” to guide care based on traits that are clinically relevant, identifiable, measurable, and possibly changeable. Arterial carbon dioxide pressure (PaCO₂) reflects factors like alveolar ventilation, dead space, respiratory mechanics, and how patients respond to ventilatory support. This makes it a clinically relevant variable in selected situations in certain situations. We carried out a scoping review using PRISMA-ScR and JBI guidelines (OSF post hoc protocol https://osf.io/vszkg) to summarize evidence on hypocapnia and hypercapnia as prognostic, stratification, or clinically relevant variables during respiratory support. We searched PubMed/MEDLINE, ScienceDirect, and Web of Science (1994–2025), and checked references by hand. Thirty-four studies met our criteria and were grouped into four areas: pre-intubation or early acute presentation, non-invasive support (NIV/HFNC), invasive mechanical ventilation, and weaning or post-extubation. In summary, hypocapnia was linked to worse outcomes or failure of support in hypoxemic or cardiogenic cases. Hypercapnia helped identify patients who benefited from NIV, such as those with COPD or obesity-hypoventilation. For invasive mechanical ventilation, the effects depended on the presence and severity of acidosis and how long it lasted. We found that PaCO₂ is measurable and clinically important, but whether it can be targeted for treatment depends on the situation. More research is needed to set safe limits and practical targets.

  • Open Access

    Diabetes Mellitus and Lipoprotein(a): A Determinant Interaction in Micro- and Macrovascular Damage

    by Alberto Polo-Barranco, Carlos Rebolledo-Maldonado, Valeria Esquiaqui-Rangel, Andrea Nuñez-Mejia, Jeisón Rambal-Torres, Valentina Barraza-Ahumada, Shivleivy Vargas-Cantillo, Wylman Benavides-De la Cruz, Valentina Liñán-Martínez, Valentina Rada-Obeso, et al.

    Even when people with diabetes mellitus (DM) meet their cholesterol goals, they still face a higher risk of heart and blood vessel problems. One major reason is a particle called lipoprotein(a), or Lp(a), which is similar to LDL cholesterol. Raised levels of Lp(a) are inherited rather than caused by lifestyle. Lp(a) can build up in the body and make it easier for blood clots to form because it closely resembles a protein called plasminogen, reducing its ability to form plasmin that dissolves blood clots. At the same time, chemical changes like oxidation and glycation can make blood vessels more inflamed, adding to the risk. Elevated concentrations of Lp(a) (>30 mg/dL; 75 nmol/L), and particularly >50 mg/dL (125 nmol/L), are independently associated with coronary artery disease, ischemic stroke, diabetic nephropathy, retinopathy, and neuropathy. Conventional lipid-lowering therapies exert neutral or modest effects on Lp(a), in contrast to RNA-based targeted agents (antisense oligonucleotides and siRNA [Small Interfering RNA]), which achieve reductions of 70–95% and show consistent results in Phase 2 clinical trials. In this review, we bring together findings from laboratory research and clinical studies, and highlight why it is important to measure Lp(a) levels—at least once in a person’s life, and especially in those with diabetes—to help doctors better assess risk and plan more effective treatments. In diabetic populations, the adaptation of Lp(a)-targeted therapies could redefine the management of residual risk and improve both cardiovascular and microvascular outcomes.